(+)-ApogossypolCAS# 66389-74-0 |
- Tubastatin A
Catalog No.:BCC2158
CAS No.:1252003-15-8
- Rocilinostat (ACY-1215)
Catalog No.:BCC2144
CAS No.:1316214-52-4
- RGFP966
Catalog No.:BCC3991
CAS No.:1357389-11-7
- M344
Catalog No.:BCC2162
CAS No.:251456-60-7
- Scriptaid
Catalog No.:BCC2163
CAS No.:287383-59-9
- Tubacin
Catalog No.:BCC2428
CAS No.:537049-40-4
Quality Control & MSDS
3D structure
Package In Stock
Number of papers citing our products
| Cas No. | 66389-74-0 | SDF | Download SDF |
| PubChem ID | 454878 | Appearance | Powder |
| Formula | C28H30O6 | M.Wt | 462.53 |
| Type of Compound | N/A | Storage | Desiccate at -20°C |
| Solubility | >16.2mg/mL in DMSO with gentle warming | ||
| Chemical Name | 3-methyl-5-propan-2-yl-2-(1,6,7-trihydroxy-3-methyl-5-propan-2-ylnaphthalen-2-yl)naphthalene-1,6,7-triol | ||
| SMILES | CC1=C(C(=C2C=C(C(=C(C2=C1)C(C)C)O)O)O)C3=C(C=C4C(=C3O)C=C(C(=C4C(C)C)O)O)C | ||
| Standard InChIKey | PBJKWGWHZVXBGU-UHFFFAOYSA-N | ||
| Standard InChI | InChI=1S/C28H30O6/c1-11(2)21-15-7-13(5)23(25(31)17(15)9-19(29)27(21)33)24-14(6)8-16-18(26(24)32)10-20(30)28(34)22(16)12(3)4/h7-12,29-34H,1-6H3 | ||
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
| About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
| Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. | ||
(+)-Apogossypol Dilution Calculator
(+)-Apogossypol Molarity Calculator
| 1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
| 1 mM | 2.162 mL | 10.8101 mL | 21.6202 mL | 43.2404 mL | 54.0505 mL |
| 5 mM | 0.4324 mL | 2.162 mL | 4.324 mL | 8.6481 mL | 10.8101 mL |
| 10 mM | 0.2162 mL | 1.081 mL | 2.162 mL | 4.324 mL | 5.4051 mL |
| 50 mM | 0.0432 mL | 0.2162 mL | 0.4324 mL | 0.8648 mL | 1.081 mL |
| 100 mM | 0.0216 mL | 0.1081 mL | 0.2162 mL | 0.4324 mL | 0.5405 mL |
| * Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. | |||||
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
- Methylsyringol
Catalog No.:BCN3535
CAS No.:6638-05-7
- TGX-221
Catalog No.:BCC1244
CAS No.:663619-89-4
- Ranitidine Hydrochloride
Catalog No.:BCC4533
CAS No.:66357-59-3
- Ranitidine
Catalog No.:BCC9134
CAS No.:66357-35-5
- 5'-Deoxy-5-fluorocytidine
Catalog No.:BCC8746
CAS No.:66335-38-4
- Dihydroguaiaretic acid
Catalog No.:BCN4212
CAS No.:66322-34-7
- ML 171
Catalog No.:BCC6252
CAS No.:6631-94-3
- 3H-1,2-Benzodithiol-3-one-1,1-dioxide
Catalog No.:BCC8633
CAS No.:66304-01-6
- Pregomisin
Catalog No.:BCN7000
CAS No.:66280-26-0
- Gomisin J
Catalog No.:BCN2270
CAS No.:66280-25-9
- 4-Amino-2-methylquinoline
Catalog No.:BCC8677
CAS No.:6628-04-2
- 6'-O-Acetylpaniculoside II
Catalog No.:BCC8316
CAS No.:
- Chloranthalactone A
Catalog No.:BCN8022
CAS No.:66395-02-6
- Chloranthalactone B
Catalog No.:BCN8020
CAS No.:66395-03-7
- 5alpha-Hydroxychloranthalactone A
Catalog No.:BCN7469
CAS No.:66395-04-8
- Pamoic acid disodium salt
Catalog No.:BCC7909
CAS No.:6640-22-8
- 13-Hydroxyoxyberberine
Catalog No.:BCN3355
CAS No.:66408-27-3
- 6-Amino-1,3-dimethyluracil
Catalog No.:BCC8755
CAS No.:6642-31-5
- 2-(2,4-Diaminophenoxy)ethanol dihydrochloride
Catalog No.:BCN8497
CAS No.:66422-95-5
- Kaempferol 3-O-(6''-O-acetyl)glucoside-7-O-rhamnoside
Catalog No.:BCN1385
CAS No.:66465-24-5
- H-D-Lys(Boc)-OMe.HCl
Catalog No.:BCC2990
CAS No.:66494-53-9
- JW 55
Catalog No.:BCC2453
CAS No.:664993-53-7
- Amantadine HCl
Catalog No.:BCC4465
CAS No.:665-66-7
- Bicifadine hydrochloride
Catalog No.:BCC7925
CAS No.:66504-75-4
Apogossypol derivative BI-97C1 (Sabutoclax) targeting Mcl-1 sensitizes prostate cancer cells to mda-7/IL-24-mediated toxicity.[Pubmed:21555592]
Proc Natl Acad Sci U S A. 2011 May 24;108(21):8785-90.
Limited options are available for treating patients with advanced prostate cancer (PC). Melanoma differentiation associated gene-7/interleukin-24 (mda-7/IL-24), an IL-10 family cytokine, exhibits pleiotropic anticancer activities without adversely affecting normal cells. We previously demonstrated that suppression of the prosurvival Bcl-2 family member, myeloid cell leukemia-1 (Mcl-1), is required for mda-7/IL-24-mediated apoptosis of prostate carcinomas. Here we demonstrate that pharmacological inhibition of Mcl-1 expression with the unique Apogossypol derivative BI-97C1, also called Sabutoclax, is sufficient to sensitize prostate tumors to mda-7/IL-24-induced apoptosis, whereas ABT-737, which lacks efficacy in inhibiting Mcl-1, does not sensitize mda-7/IL-24-mediated cytotoxicity. A combination regimen of tropism-modified adenovirus delivered mda-7/IL-24 (Ad.5/3-mda-7) and BI-97C1 enhances cytotoxicity in human PC cells, including those resistant to mda-7/IL-24 or BI-97C1 alone. The combination regimen causes autophagy that facilitates NOXA- and Bim-induced and Bak/Bax-mediated mitochondrial apoptosis. Treatment with Ad.5/3-mda-7 and BI-97C1 significantly inhibits the growth of human PC xenografts in nude mice and spontaneously induced PC in Hi-myc transgenic mice. Tumor growth inhibition correlated with increased TUNEL staining and decreased Ki-67 expression in both PC xenografts and prostates of Hi-myc mice. These findings demonstrate that pharmacological inhibition of Mcl-1 with the Apogossypol derivative, BI-97C1, sensitizes human PCs to mda-7/IL-24-mediated cytotoxicity, thus potentially augmenting the therapeutic benefit of this combinatorial approach toward PC.
Inhibitory activity of apogossypol in human prostate cancer in vitro and in vivo.[Pubmed:25672487]
Mol Med Rep. 2015 Jun;11(6):4142-8.
Apogossypol, a gossypol derivative, is a novel smallmolecule inhibitor of the Bcl2 family proteins and has been demonstrated to have antitumor activities. Prostate cancer is the most common malignancy in males, for which chemotherapy is the usual treatment option in clinical practice. The aim of the present study was to investigate the growth inhibitory effects of apogossypol on prostate cancers in vitro and in vivo. An MTT assay and a colony formation assay were used to assess the antisurvival and antiproliferation effects of apogossypol in LNCaP cells. Immunofluorescence was performed in order to detect the expression levels of apoptosisassociated proteins in xenograft tumors following apogossypol treatment. Apogossypol exerted strong antitumor effects on LNCaP cells in a dosedependent manner. Furthermore, immunofluorescence revealed that apogossypol inhibited the growth and proliferation of prostate cancer cells by downregulating Bcl2 protein expression and activating caspase3 and 8. In addition, the in vivo study indicated that apogossypol significantly inhibited tumor growth in a dosedependent manner with reduced toxicity compared with gossypol. In conclusion, the present study indicated that apogossypol effectively inhibited the growth and proliferation of prostate cancer cells and may be a potential agent for prostate cancer therapy.
BI-97C1, an optically pure Apogossypol derivative as pan-active inhibitor of antiapoptotic B-cell lymphoma/leukemia-2 (Bcl-2) family proteins.[Pubmed:20443627]
J Med Chem. 2010 May 27;53(10):4166-76.
In our continued attempts to identify novel and effective pan-Bcl-2 antagonists, we have recently reported a series of compound 2 (Apogossypol) derivatives, resulting in the chiral compound 4 (8r). We report here the synthesis and evaluation on its optically pure individual isomers. Compound 11 (BI-97C1), the most potent diastereoisomer of compound 4, inhibits the binding of BH3 peptides to Bcl-X(L), Bcl-2, Mcl-1, and Bfl-1 with IC(50) values of 0.31, 0.32, 0.20, and 0.62 microM, respectively. The compound also potently inhibits cell growth of human prostate cancer, lung cancer, and lymphoma cell lines with EC(50) values of 0.13, 0.56, and 0.049 microM, respectively, and shows little cytotoxicity against bax(-/-)bak(-/-) cells. Compound 11 displays in vivo efficacy in transgenic mice models and also demonstrated superior single-agent antitumor efficacy in a prostate cancer mouse xenograft model. Therefore, compound 11 represents a potential drug lead for the development of novel apoptosis-based therapies against cancer.
Enhanced delivery of mda-7/IL-24 using a serotype chimeric adenovirus (Ad.5/3) in combination with the Apogossypol derivative BI-97C1 (Sabutoclax) improves therapeutic efficacy in low CAR colorectal cancer cells.[Pubmed:21780116]
J Cell Physiol. 2012 May;227(5):2145-53.
Adenovirus (Ad)-based gene therapy represents a potentially viable strategy for treating colorectal cancer. The infectivity of serotype 5 adenovirus (Ad.5), routinely used as a transgene delivery vector, is dependent on Coxsackie-adenovirus receptors (CAR). CAR expression is downregulated in many cancers thus preventing optimum therapeutic efficiency of Ad.5-based therapies. To overcome the low CAR problem, a serotype chimerism approach was used to generate a recombinant Ad (Ad.5/3) that is capable of infecting cancer cells via Ad.3 receptors in a CAR-independent manner. We evaluated the improved transgene delivery and efficacy of Ad.5/3 recombinant virus expressing melanoma differentiation associated gene-7/interleukin-24 (mda-7/IL-24), an effective wide-spectrum cancer-selective therapeutic. In low CAR human colorectal cancer cells RKO, wild-type Ad.5 virus expressing mda-7/IL-24 (Ad.5-mda-7) failed to infect efficiently resulting in lack of expression of MDA-7/IL-24 or induction of apoptosis. However, a recombinant Ad.5/3 virus expressing mda-7/IL-24 (Ad.5/3-mda-7) efficiently infected RKO cells resulting in higher MDA-7/IL-24 expression and inhibition of cell growth both in vitro and in nude mice xenograft models. Addition of the novel Bcl-2 family pharmacological inhibitor Apogossypol derivative BI-97C1 (Sabutoclax) significantly augmented the efficacy of Ad.5/3-mda-7. A combination regimen of suboptimal doses of Ad.5/3-mda-7 and BI-97C1 profoundly enhanced cytotoxicity in RKO cells both in vitro and in vivo. Considering the fact that Ad.5-mda-7 has demonstrated significant objective responses in a Phase I clinical trial for advanced solid tumors, Ad.5/3-mda-7 alone or in combination with BI-97C1 would be predicted to exert significantly improved therapeutic efficacy in colorectal cancer patients.
